SAN JOSE, Calif.—The global market for Intravenous (IV) Iron Drugs is forecast to reach $1.6 billion by the year 2015, according to a report market research company Global Industry Analysts Inc. (GIA).
Key factors driving market growth include increasing population of chronic kidney disease patients and the pricing of the product, according to GIA. Other factors propelling market growth include increasing hemodialysis patient population, and limitations of other iron replacement therapies.
“Due to the non-discretionary nature of most of the medical expenditures, the pharmaceutical industry, and consequently the IV iron drugs market, continued to expand during recession,” GIA said in a news release. “With increase in lifestyle-related ailments, improved life expectancy rate, the aging population, as well as soaring healthcare expenses across the world, the IV iron drugs market worldwide is expected to experience sizable growth in the near future too.”
A prominent trend in the IV iron drugs market is the increased popularity of dialysis clinics, as they form a very significant customer group for intravenous iron drugs. In addition to providing dialysis treatments, such centers also administer iron dosages. “The clinics are constantly on the look out for IV iron supplements that are reliable, safe, and have less administration time,” GIA said.
Major players profiled in the report include AMAG Pharmaceuticals Inc, Fresenius Medical Care AG & Co. KGaA, Galenica Ltd., Vifor Pharma Ltd, Luitpold Pharmaceuticals Inc, American Regent Inc, Pharmacosmos A/S, Rockwell Medical Technologies Inc, Sanofi-Aventis U.S. LLC, Syner-Med (Pharmaceutical Products) Ltd, and Watson Pharmaceuticals Inc.
